Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

Eduard Shantsila, S Montoro-García, Luke Tapp, Stavros Apostolakis, BJ Wrigley, Gregory Lip

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p
Original languageEnglish
JournalThrombosis and Haemostasis
Volume108
Issue number1
DOIs
Publication statusPublished - 27 Apr 2012

Fingerprint

Dive into the research topics of 'Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.'. Together they form a unique fingerprint.

Cite this